Asymmetric dimethylarginine reflects cumulative inflammatory burden in rheumatoid arthritis

Włoch, Alicja; Wieczorek-Surdacka, Ewa; Sulicka-Grodzicka, Joanna; Kruszelnicka, Olga; Surdacki, Andrzej

doi:10.1093/rheumatology/kev104

Cited by 4 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asymmetric dimethyl arginine and symmetric dimethylarginine are potential biomarkers of cumulative inflammatory vascular damage and cardiovascular disease in RA. [143][144][145] The use of biomarkers in risk-prediction models to improve cardiovascular risk stratification was demonstrated in a large European population wherein additional measurement of the combination of N-terminal pro-brain natriuretic peptide, CRP and troponin I led to an improved 10-year-risk estimation, compared with a conventional-risk-factor model alone. 146 The value of these biomarkers for risk prediction in the presence of IJDs is not known.…”

Section: Biomarkersmentioning

confidence: 99%

Cardiovascular comorbidity in rheumatic diseases

2015

View full text Add to dashboard Cite

Patients with rheumatoid arthritis (RA) and other inflammatory joint diseases (IJDs) have an increased risk of premature death compared with the general population, mainly because of the risk of cardiovascular disease, which is similar in patients with RA and in those with diabetes mellitus. Pathogenic mechanisms and clinical expression of cardiovascular comorbidities vary greatly between different rheumatic diseases, but atherosclerosis seems to be associated with all IJDs. Traditional risk factors such as age, gender, dyslipidaemia, hypertension, smoking, obesity and diabetes mellitus, together with inflammation, are the main contributors to the increased cardiovascular risk in patients with IJDs. Although cardiovascular risk assessment should be part of routine care in such patients, no disease-specific models are currently available for this purpose. The main pillars of cardiovascular risk reduction are pharmacological and nonpharmacological management of cardiovascular risk factors, as well as tight control of disease activity.

show abstract

Section: Biomarkersmentioning

confidence: 99%

Cardiovascular comorbidity in rheumatic diseases

2015

View full text Add to dashboard Cite

show abstract

Rheumatoid Arthritis

Dimitroulas

Sandoo

Skeoch

et al. 2017

The Heart in Rheumatic, Autoimmune and Inflammatory Diseases

View full text Add to dashboard Cite

Comorbidity in rheumatoid arthritis: A focus on cardiovascular diseases

Gasparyan

Kanevskaya

2016

Klin. med.

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) in patients with rheumatoid arthritis (RA) are ranked first in the structure of comorbidity and mortality. This review includes recent data on common pathogenic mechanisms of inflammation and atherosclerosis, the impact of traditional and specific risk factors, biomarkers of CVD in RA patients. Variants of CVD in RA, the possible pathogenic mechanisms of their development and methods of diagnosis and prevention are described.

show abstract

Asymmetric dimethylarginine reflects cumulative inflammatory burden in rheumatoid arthritis

Cited by 4 publications

References 11 publications

Cardiovascular comorbidity in rheumatic diseases

Cardiovascular comorbidity in rheumatic diseases

Rheumatoid Arthritis

Comorbidity in rheumatoid arthritis: A focus on cardiovascular diseases

Contact Info

Product

Resources

About